Targeted Oncology™ is proud to celebrate 10 years of providing oncology health care professionals in community settings with the most up-to-date information through innovative learning formats and valued peer-to-peer engagements. We are fully committed, along with the broader oncology community, to another decade of driving knowledge, empowering
change, and optimizing outcomes.
December 01, 2022
"We should continue to see steady gains in new targets and improvements in our targeted therapies that make these options available for an ever-larger subgroup of patients with non–small cell lung cancer who can derive longer duration of benefit from additional lines of treatment," says H. Jack West, MD.
October 17, 2022
As we identify more targets...there will probably be more and newer, perhaps even better, therapeutics than we have currently, said Dennis J. Slamon, MD.
September 27, 2022
Targeted Therapies in Oncology asked some experts in prostate cancer diagnostics and therapeutics for their thoughts on the milestone improvements in treating patients with prostate cancer over the past decade.
August 26, 2022
According to experts, routine biomarker testing has become a standard part of care for several common tumor types.
July 25, 2022
Many clinicians believe the most significant advance in LBCL treatment in this time is the development of chimeric antigen receptor T-cell therapy.
June 19, 2022
The last decade of immunotherapy progress was based on decades of prior research, including other forms of immunotherapy.
May 23, 2022
Ongoing and proposed melanoma research will naturally continue to evaluate new treatment types.
April 14, 2022
The past decade has seen the FDA approve a handful of new targeted therapies for chronic lymphocytic leukemia that are prompting a move toward chemotherapy-free treatment of the disease.
March 28, 2022
Treatment options have expanded widely for patients with multiple myeloma over the past several years, resulting in significantly improved outcomes for these patients.
February 03, 2022
Tanios S. Bekaii-Saab, MD, FACP, Richard S. Finn, MD, and William P. Harris, MD, highlight advances in research and clinical treatment of hepatocellular carcinoma over the past 10 years.